Recent Updates
Recently added Catalysts

NTHi-10-AS01E

Phase 2

Respiratory Disorders | Monoclonal antibody | Other |GSK plc|Last Updated: Aug 1, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment145
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02075541A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.PHASE2 COMPLETED 145Jul 8, 2014Apr 19, 2017Aug 1, 201814 Sweden, United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Any Solicited Local Adverse Events (AEs).
During a 7-day follow-up period (from Day 0 to Day 6) after first dose.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Number of Subjects With Any Solicited Local AEs.
During a 7-day follow-up period (from Day 60 to Day 66) after second dose.

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Number of Subjects With Any Solicited General AEs.
During a 7-day follow-up period (from Day 0 to Day 6) following the first dose.

Assessed solicited general symptoms are fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, fever \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade.

Number of Subjects With Any Solicited General AEs
During a 7-day follow-up period (from Day 60 to Day 66) following the second dose.

Assessed solicited general symptoms are fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhoea and/or abdominal pain), headache, fever (defined as oral temperature equal to or above 37.5 °C). Any = occurrence of the symptom regardless of intensity grade.

Number of Subjects With Any Unsolicited AEs.
During the 30-day follow-up period (from Day 0 to Day 29) following the first dose.

Assessed unsolicited AEs covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.

Number of Subjects With Any Unsolicited AEs
During the 30-day follow-up period (from Day 60 to Day 89) following the second dose.

Assessed unsolicited AEs covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.

Number of Subjects With Each Haematological/ Biochemical Laboratory Abnormality.
At Day 0.

Assessed haematological parameters are complete blood cell count: Leukocytes \[white blood cells (WBC)\], differential count (basophils, eosinophils, lymphocytes, monocytes, neutrophils), platelets count, and hemoglobin level below or above the normal laboratory ranges tabulated by time point. Assessed biochemical parameters are alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatinine below or above the normal laboratory ranges tabulated by time point.

Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs).
From first vaccination (Day 0) up to study conclusion (Day 450).

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Number of Subjects With Any Serious Adverse Events (SAEs).
From first vaccination (Day 0) up to study conclusion (Day 450).

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject.

Secondary Endpoints
Concentration of Anti Protein D (Anti-PD) Total Immunoglobulin G (IgG) Antibodies Against the NTHi Vaccine Antigens.
At Day 0, Day 30, Day 60, Day 90, Day 270 and at Day 450.
Concentration of Anti Protein E (Anti-PE) Total IgG Antibodies Against the NTHi Vaccine Antigens.
At Day 0, Day 30, Day 60, Day 90, Day 270 and at Day 450
Concentration of Anti-PilA Total IgG Antibodies Against the NTHi Vaccine Antigens.
At Day 0, Day 30, Day 60, Day 90, Day 270 and at Day 450.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
10-AS01E groupEXPERIMENTALSubjects in this group will receive the investigational NTHi vaccine.
Control groupPLACEBO_COMPARATORSubjects in this group will receive placebo.
Interventions
NameTypeDescription
NTHi-10-AS01EBIOLOGICALIntramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
NaCl PlaceboDRUGIntramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites14

Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * A male or female between, and including, 40 and 80 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * Confirme...

Countries:SwedenUnited Kingdom
Unlock Eligibility Criteria